Cargando…
Targeting MET in cancer therapy
MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. MET exon 14 alterations and MET gene amplification play a critical role in th...
Autores principales: | Mo, Hong-Nan, Liu, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643781/ https://www.ncbi.nlm.nih.gov/pubmed/29063069 http://dx.doi.org/10.1016/j.cdtm.2017.06.002 |
Ejemplares similares
-
The Occurrence of MET Ectodomain Shedding in Oral Cancer and Its Potential Impact on the Use of Targeted Therapies
por: De Herdt, Maria J., et al.
Publicado: (2022) -
Progress in targeted therapy for breast cancer
por: Ju, Jie, et al.
Publicado: (2018) -
Metabolic Reprogramming by c-MET Inhibition as a Targetable Vulnerability in Glioblastoma
por: Thi Thu Nguyen, Trang, et al.
Publicado: (2020) -
The limits of human microRNA annotation have been met
por: Fromm, Bastian, et al.
Publicado: (2022) -
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)